Seeking Alpha

Elan (ELN +3.8%) intends to spin off its loss-making Neotope drug-discovery unit into a separate...

Elan (ELN +3.8%) intends to spin off its loss-making Neotope drug-discovery unit into a separate publicly traded company, a move that will make Elan immediately profitable and could fuel speculation that it will be a more attractive acquisition target for Biogen (BIIB), which is the firm's partner for its Tysabri multiple sclerosis drug. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|